Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Acadia Healthcare Company Inc (ACHC) vs Heron Therapeutics Inc (HRTX) Price & Performance

Acadia Healthcare Company IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Acadia Healthcare Company Inc vs Heron Therapeutics Inc — how do they compare? Acadia Healthcare Company Inc trades at $31.18 (market cap $2.96B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Acadia Healthcare Company Inc is far larger — about 46.7× Heron Therapeutics Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

ACHCHRTX
Market Cap
$2.96B$63.41M
Sector
HealthHealth
52-Week High
$35.61$1.49
52-Week Low
$11.68$0.32
Enterprise Value
$5.35B$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Acadia Healthcare Company Inc

ACHC trades at $31.53, up 2.64% today, with a neutral technical signal despite bullish moving averages. The company shows strong revenue growth with Q2 2026 earnings beating estimates, but faces profitability challenges with negative net income margins. Analyst consensus remains positive with 68% buy ratings and a $36 price target, though ongoing legal investigations create headwinds.

The outlook balances operational strength against financial risks. Revenue growth and facility expansion support upside potential, but negative profitability and legal uncertainties warrant caution. The stock offers 14% upside to consensus target if execution improves, but investors should monitor earnings sustainability and legal developments closely.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Acadia Healthcare Company Inc

Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.

Read more on ACHC

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX